Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer - PubMed (original) (raw)

• PMID: 16575875
• DOI: 10.1002/gcc.20329

Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer

Maria Johansson Soller et al. Genes Chromosomes Cancer. 2006 Jul.

No abstract available

PubMed Disclaimer

Similar articles

• Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
  Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM. Laxman B, et al. Neoplasia. 2006 Oct;8(10):885-8. doi: 10.1593/neo.06625. Neoplasia. 2006. PMID: 17059688 Free PMC article.
• Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
  Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA. Yoshimoto M, et al. Neoplasia. 2006 Jun;8(6):465-9. doi: 10.1593/neo.06283. Neoplasia. 2006. PMID: 16820092 Free PMC article.
• TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
  Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. Hermans KG, et al. Cancer Res. 2006 Nov 15;66(22):10658-63. doi: 10.1158/0008-5472.CAN-06-1871. Cancer Res. 2006. PMID: 17108102
• Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
  Hossain D, Bostwick DG. Hossain D, et al. BJU Int. 2013 May;111(5):834-5. doi: 10.1111/bju.12120. BJU Int. 2013. PMID: 23578235 Review. No abstract available.
• [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
  Guo XQ, Gui YT, Cai ZM. Guo XQ, et al. Yi Chuan. 2011 Feb;33(2):117-22. doi: 10.3724/sp.j.1005.2011.00117. Yi Chuan. 2011. PMID: 21377967 Review. Chinese.

Cited by

• Applications of Urinary Extracellular Vesicles in the Diagnosis and Active Surveillance of Prostate Cancer.
  Smith SF, Brewer DS, Hurst R, Cooper CS. Smith SF, et al. Cancers (Basel). 2024 Apr 28;16(9):1717. doi: 10.3390/cancers16091717. Cancers (Basel). 2024. PMID: 38730670 Free PMC article. Review.
• The potential role of the microbiota in prostate cancer pathogenesis and treatment.
  Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M, Liu L, Maraccani L, Guccini I, Migliorini D, de Bono J, Alimonti A. Pernigoni N, et al. Nat Rev Urol. 2023 Dec;20(12):706-718. doi: 10.1038/s41585-023-00795-2. Epub 2023 Jul 25. Nat Rev Urol. 2023. PMID: 37491512 Review.
• Fusion sequencing via terminator-assisted synthesis (FTAS-seq) identifies TMPRSS2 fusion partners in prostate cancer.
  Drazdauskienė U, Kapustina Ž, Medžiūnė J, Dubovskaja V, Sabaliauskaitė R, Jarmalaitė S, Lubys A. Drazdauskienė U, et al. Mol Oncol. 2023 Jun;17(6):993-1006. doi: 10.1002/1878-0261.13428. Epub 2023 Apr 13. Mol Oncol. 2023. PMID: 37300660 Free PMC article.
• Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer.
  Newtson A, Reyes H, Devor EJ, Goodheart MJ, Bosquet JG. Newtson A, et al. Int J Mol Sci. 2021 Apr 30;22(9):4791. doi: 10.3390/ijms22094791. Int J Mol Sci. 2021. PMID: 33946483 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information